Related references
Note: Only part of the references are listed.Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Haizhen Wang et al.
NATURE (2017)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2017)
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer
Uzma S. Asghar et al.
CLINICAL CANCER RESEARCH (2017)
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Eric Raspe et al.
EMBO MOLECULAR MEDICINE (2017)
New agents for endocrine resistance in breast cancer
Christian Maurer et al.
BREAST (2017)
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors
Debu Tripathy et al.
CLINICAL CANCER RESEARCH (2017)
Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice
Yu Jin Lim et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study
L. Gianni et al.
CANCER RESEARCH (2017)
Single agent palbociclib with or without trastuzumab for the treatment of Rb plus advanced breast cancer
A. S. Clark et al.
CANCER RESEARCH (2017)
CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Ana C. Garrido-Castro et al.
CURRENT BREAST CANCER REPORTS (2017)
CDK4/6 inhibitors in HER2-positive breast cancer
Silvia Paola Corona et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers
D. Fumagalli et al.
ANNALS OF ONCOLOGY (2016)
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Shom Goel et al.
CANCER CELL (2016)
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer
Yutaka Fujiwara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Endocrine treatment in breast cancer: Cure, resistance and beyond
Konstantinos Tryfonidis et al.
CANCER TREATMENT REVIEWS (2016)
Targeted adjuvant therapy in breast cancer
Dimitrios Zardavas et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni et al.
ONCOTARGET (2016)
New generation of breast cancer clinical trials implementing molecular profiling
Dimitrios Zardavas et al.
CANCER BIOLOGY & MEDICINE (2016)
OOTR-N007: A phase II neoadjuvant study of letrozole plus palbociclib in postmenopausal patients with ER positive, HER2 negative breast cancer
Louis W. C. Chow et al.
CANCER RESEARCH (2015)
Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance
Hilal S. Khalil et al.
JOURNAL OF BIOTECHNOLOGY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Clinical management of breast cancer heterogeneity
Dimitrios Zardavas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
Angela DeMichele et al.
CLINICAL CANCER RESEARCH (2015)
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Thomas J. Raub et al.
DRUG METABOLISM AND DISPOSITION (2015)
The AURORA initiative for metastatic breast cancer
D. Zardavas et al.
BRITISH JOURNAL OF CANCER (2014)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
Emerging targeted agents in metastatic breast cancer
Dimitrios Zardavas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Control of cell cycle transcription during G1 and S phases
Cosetta Bertoli et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Cell cycle control across the eukaryotic kingdom
Hirofumi Harashima et al.
TRENDS IN CELL BIOLOGY (2013)
Signaling Pathways that Control Cell Proliferation
Robert J. Duronio et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
Jeffry L. Dean et al.
CELL CYCLE (2012)
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
A. Kathleen McClendon et al.
CELL CYCLE (2012)
Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
Keith T. Flaherty et al.
CLINICAL CANCER RESEARCH (2012)
The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2012)
Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer
Yoshimi Arima et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
G. K. Schwartz et al.
BRITISH JOURNAL OF CANCER (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 Methyltransferase
Priya Aggarwal et al.
CANCER CELL (2010)
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status
Zhe Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Driving the cell cycle with a minimal CDK control network
Damien Coudreuse et al.
NATURE (2010)
Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen
Frederic Bienvenu et al.
NATURE (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
A. Satyanarayana et al.
ONCOGENE (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Positive feedback of G1 cyclins ensures coherent cell cycle entry
Jan M. Skotheim et al.
NATURE (2008)
Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation
Linsheng Zhang et al.
BLOOD (2008)
The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas
Jason I. Herschkowitz et al.
BREAST CANCER RESEARCH (2008)
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
M. N. Fornier et al.
CLINICAL CANCER RESEARCH (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
The regulation of INK4/ARF in cancer and aging
William Y. Kim et al.
CELL (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cyclins: Roles in mitogenic signaling and oncogenic transformation
EA Musgrove
GROWTH FACTORS (2006)
Requirement for CDK4 kinase function in breast cancer
QY Yu et al.
CANCER CELL (2006)
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from cancer and leukemia group B study 19805
JC Byrd et al.
CLINICAL CANCER RESEARCH (2005)
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer
AR Tan et al.
CLINICAL CANCER RESEARCH (2004)
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer
J Lamb et al.
CELL (2003)
Developmental Therapeutics Program at the NCI: molecular target and drug discovery process
M Monga et al.
LEUKEMIA (2002)
Cyclin-dependent kinases
JW Harper et al.
CHEMICAL REVIEWS (2001)
Specific protection against breast cancers by cyclin D1 ablation
QY Yu et al.
NATURE (2001)
Share Paper
